Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 940602 | ISIN: NL0000009538 | Ticker-Symbol: PHI1
Tradegate
21.11.24
21:18 Uhr
25,170 Euro
+0,190
+0,76 %
1-Jahres-Chart
KONINKLIJKE PHILIPS NV Chart 1 Jahr
5-Tage-Chart
KONINKLIJKE PHILIPS NV 5-Tage-Chart
RealtimeGeldBriefZeit
25,09025,18022:59
25,07025,16022:00
GlobeNewswire (Europe)
502 Leser
Artikel bewerten:
(2)

Royal Philips: Philips ePatch and AI analytics platform rolled out to 14 hospitals across Spain to monitor heart patients

Finanznachrichten News

May 22, 2024

  • Philips wearable ePatch and AI analytics platform help detect potentially life-threatening irregular heartbeats
  • The solution helps University Hospital Vall d'Hebron achieve reduced average length of stay, relieve emergency room pressure, and reduce costs

Amsterdam, the Netherlands, and Madrid, Spain - Royal Philipspaired with its AI-driven Cardiologsanalytics platform. 14 Spanish healthcare providers across the country are now using the company's ePatch extended wear Holter monitors to detect life-threatening heart arrhythmias such as atrial fibrillation (AF). The solution has been proven to detect heart arrhythmias missed by traditional Holter monitors, enhance patient comfort, improve care access, and potentially better clinical outcomes, in addition to reducing overall costs.

Philips' ePatch provides reliable data for up to 14 days of continuous monitoring. When paired with Philips' AI-driven Cardiologsanalytics platform, the solution empowers the hospitals' cardiology and neurology teams with an end-to-end solution that enhances their ability to detect and diagnose AF - a potentially life-threatening [1] cardiac arrhythmia and also the world's most common. AF significantly increases the risk of stroke, dementia, and heart failure, yet often goes undetected due to its lack of noticeable symptoms and infrequent occurrence intervals.

"The key advantage for healthcare professionals lies in its user-friendly interface and high-quality 14-day continuous recording capabilities," said Dr. Jorge Pagola, Neurologist Postdoctoral Researcher at University Hospital Vall d'Hebron, Barcelona, Spain. "Applied as a chest patch in just a few minutes, it seamlessly integrates an analysis program, facilitating swift examination of recordings. Thanks to its AI-based analysis assistant, AF events can be classified for rapid review by our team. Patients experience enhanced comfort as they are free from cumbersome cables of the conventional Holter, allowing them to dress, shower, and carry out their daily activities without any hindrance."

Dr. Jorge Pagola further explains, "Using the ePatch program, we expedited hospital discharge for 80 patients in 2023. This initiative led to a reduced average length of stay, relieved emergency room pressure, and an estimated total cost reduction of € 28.800 in 2023 [2]."

Pilot programs in major hospitals across Spain
In addition to Hospital Vall d'Hebron, where Philips' ePatch is being used to detect post-discharge AF in patients, pilot projects demonstrating the device's effectiveness in cardiology and neurology are being conducted at other major hospitals in Madrid, Barcelona, Bilbao, Alicante, Madrid, Cadiz, and Navarra [3]. Applications include monitoring patients for AF after cardiac ablation therapy or heart valve replacement procedures, and studies of the link between magnesium insufficiency and AF.

In some Spanish hospitals, the ease-of-use and cost benefits of Philips ePatch are helping reduce waiting lists that built up during the COVID-19 pandemic, making a tangible difference to people's access to care. In total, more than 1500 patients are currently being monitored with Philips ePatch devices in Spain.

"This innovative new service allows clinical teams to conveniently monitor patients as they go about their everyday activities for extended periods of time, collecting the real-life data that helps reveal the patient's true condition," said Miquel Barras, Ambulatory Monitoring & Diagnostics Lead for Philips in Spain.

In a recent US study comparing the diagnostic abilities of 7-day and 14-day monitoring with Philips' extended wear ePatch compared to conventional 24-hour Holter monitoring, the ePatch detected 2x more clinically significant heart arrhythmias during 7 days of monitoring and more than 2.5x as many over 14 days [4].

[1] Heart.org
[2] Data on file in hospital Vall d'Hebron
[3] Madrid: Hospital Universitario Fundación Jiménez Díaz, Hospital Universitario Infanta Elena, Hospital de La Princesa, University Hospital Quironsalud Madrid, Hospital Universitario Rey Juan Carlos. Barcelona: Vall d'Hebron University Hospital, Hospital Clínic de Barcelona, Hospital de Sant Joan Despí Moisès Broggi, Hospital Sant Joan de Déu Barcelona, Hospital Universitari de Bellvitge, Hospital de Sant Pau. Bilbao: Hospital Universitario Cruces. Alicante: Hospital General Universitario de Elche. Cadiz: Hospital Universitario De Jerez. Navarra: Hospital General de Navarra.
[4] Parikh, P, Grigoriadis, C, Dunn, A. et al. Diagnostic Yield of 24-hour Holter vs 7-day and 14-day ePatch Extended Wear Holter. J Am Coll Cardiol. 2023 Mar, 81

For further information, please contact:

César García Requena
Philips Ibérica
Tel: +34 670 264 471
Email: cesar.garcia.requena@philips.com

Joost Maltha
External Relations
Tel: +31 6 10 55 8116
Email: joost.maltha@philips.com

About Royal Philips

Royal Philips.

Attachments

  • Woman wearing Philips ePatch (https://ml-eu.globenewswire.com/Resource/Download/c298f826-c288-470e-8152-7ae22329fc48)
  • Philips ePatch (https://ml-eu.globenewswire.com/Resource/Download/b26b537c-c90b-4de1-b5c9-1ea9b4894614)
  • Dr. Jorge Pagola Val dHebron (https://ml-eu.globenewswire.com/Resource/Download/a7f48f2e-ab75-4aba-abce-f80b4f251df5)
  • Philips Cardiologs AI analytics platform (https://ml-eu.globenewswire.com/Resource/Download/48fc9f23-2cb8-49c0-af45-68f8e01c3ece)

© 2024 GlobeNewswire (Europe)
Treibt Nvidias KI-Boom den Uranpreis?
In einer Welt, in der künstliche Intelligenz zunehmend zum Treiber technologischer Fortschritte wird, rückt auch der Energiebedarf, der für den Betrieb und die Weiterentwicklung von KI-Systemen erforderlich ist, in den Fokus.

Nvidia, ein Vorreiter auf dem Gebiet der KI, steht im Zentrum dieser Entwicklung. Mit steigender Nachfrage nach leistungsfähigeren KI-Anwendungen steigt auch der Bedarf an Energie. Uran, als Schlüsselkomponente für die Energiegewinnung in Kernkraftwerken, könnte dadurch einen neuen Stellenwert erhalten.

Dieser kostenlose Report beleuchtet, wie der KI-Boom potenziell den Uranmarkt beeinflusst und stellt drei aussichtsreiche Unternehmen vor, die von diesen Entwicklungen profitieren könnten und echtes Rallyepotenzial besitzen

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von der steigenden Nachfrage, der den Uranpreis auf neue Höchststände treiben könnte.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.